March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Treatment With Recombinant Interleukin-17A Reduces ARPE-19 Cell Viability
Author Affiliations & Notes
  • Daniel Ardeljan
    Immunopathology Section/Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Yujuan Wang
    Immunopathology Section/Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • De Fen Shen
    Immunopathology Section/Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Jingsheng Tuo
    Immunopathology Section/Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Chi-Chao Chan
    Immunopathology Section/Laboratory of Immunology, National Eye Institute/NIH, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  Daniel Ardeljan, None; Yujuan Wang, None; De Fen Shen, None; Jingsheng Tuo, None; Chi-Chao Chan, None
  • Footnotes
    Support  NIH Intramural Fund
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel Ardeljan, Yujuan Wang, De Fen Shen, Jingsheng Tuo, Chi-Chao Chan; Treatment With Recombinant Interleukin-17A Reduces ARPE-19 Cell Viability. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1227.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Age-related macular degeneration (AMD) is a degenerative disease that impairs primarily photoreceptors and the retinal pigment epithelium (RPE) in the macula. Recently, expression of significantly higher IL-17A transcripts was found in human AMD maculae and elevated serum IL-17A levels were measured in AMD patients. IL-17A is known to induce a robust immune response, but its exact effect on the RPE remains elusive. This study explores the role of IL-17A in human RPE cells.

Methods: : Cultured ARPE-19 cells were serum-starved for 24h and then treated for 48h with recombinant IL-17A (100 ng/ml). A Taqman gene expression array of 92 human signal transduction genes revealed IL-8 to be differentially expressed after the treatment, which was further examined by quantitative RT-PCR. An experiment to characterize the role of NF-kB, the upstream regulator of IL-8, was conducted by co-incubating IL-17A and an NF-kB inhibitor (SN50, 18μM) with ARPE-19 cells. Apoptosis was evaluated by immunohistochemical detection of Caspase-3 and Caspase-9 activation and by flow cytometry using Annexin V/7AAD. An MTT assay was performed to evaluate ARPE-19 cell viability with respect to changes in IL-17A doses.

Results: : IL-17A-treated ARPE-19 cells had substantially increased IL-8 mRNA along with elevated Caspase-9 activity and diminished Caspase-3 activity as detected by immunohistochemistry. Inhibition of NF-kB with SN50 resulted in increased apoptotic activity as measured by flow cytometry and this effect was marginally strengthened with the addition of IL-17A. The MTT assay revealed that IL-17A doses ranging from 1 pg/ml to 10 ug/ml decreased cell viability from approximately 20-35%.

Conclusions: : IL-17A might play a role in the apoptosis of RPE cells and IL-8 might be one of its major mediators. IL-17A-treated ARPE-19 cells exhibit altered caspase activity in a process largely but not completely mediated by the NF-kB pathway. IL-17A was shown to have a negative effect on cell viability in culture. It seems that IL-17A is not only a mediator of inflammation, but also a regulator of apoptosis.

Keywords: cytokines/chemokines • retinal pigment epithelium • cell survival 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×